Grufity logoGrufity logo
Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ZTS

ZTS - Zoetis Inc Stock Price, Fair Value and News

164.97USD-3.48 (-2.07%)Market Closed

Market Summary

ZTS
USD164.97-3.48
Market Closed
-2.07%

ZTS Alerts

  • 1 major insider sales recently.

ZTS Stock Price

View Fullscreen

ZTS RSI Chart

ZTS Valuation

Market Cap

75.3B

Price/Earnings (Trailing)

31.48

Price/Sales (Trailing)

8.62

EV/EBITDA

21.43

Price/Free Cashflow

43.01

ZTS Price/Sales (Trailing)

ZTS Profitability

EBT Margin

34.19%

Return on Equity

47.33%

Return on Assets

16.66%

Free Cashflow Yield

2.32%

ZTS Fundamentals

ZTS Revenue

Revenue (TTM)

8.7B

Rev. Growth (Yr)

9.5%

Rev. Growth (Qtr)

-1.04%

ZTS Earnings

Earnings (TTM)

2.4B

Earnings Growth (Yr)

8.51%

Earnings Growth (Qtr)

14.1%

Breaking Down ZTS Revenue

Last 7 days

4.1%

Last 30 days

-0.4%

Last 90 days

-15.7%

Trailing 12 Months

-10.5%

How does ZTS drawdown profile look like?

ZTS Financial Health

Current Ratio

3.33

Debt/Equity

1.3

Debt/Cashflow

0.37

ZTS Investor Care

Dividend Yield

0.98%

Dividend/Share (TTM)

1.61

Buy Backs (1Y)

1.26%

Diluted EPS (TTM)

5.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20248.7B000
20238.1B8.2B8.4B8.5B
20227.9B8.0B8.0B8.1B
20217.0B7.4B7.6B7.8B
20206.3B6.3B6.5B6.7B
20195.9B6.0B6.2B6.3B
20185.4B5.6B5.7B5.8B
20175.0B5.0B5.1B5.3B
20164.8B4.9B4.9B4.9B
20154.8B4.8B4.8B4.8B
20144.6B4.6B4.7B4.8B
20134.4B4.4B4.5B4.6B
20124.3B4.3B4.3B4.3B
20113.7B3.9B4.1B4.2B
20100003.6B
Get all data in R, Python etc through our Historical Stock Data APIs
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Zoetis Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 18, 2024
lagano roxanne
sold
-139,530
151
-923
executive vice president
Mar 18, 2024
lagano roxanne
sold
-319,967
173
-1,846
executive vice president
Mar 11, 2024
reed willie m
sold
-250,265
182
-1,370
-
Feb 21, 2024
norden gregory
gifted
-
-
-2,214
-
Feb 20, 2024
lagano roxanne
sold
-172,878
187
-923
executive vice president
Feb 20, 2024
peck kristin c
acquired
599,170
46.09
13,000
chief executive officer
Feb 20, 2024
peck kristin c
sold
-2,433,640
187
-13,000
chief executive officer
Feb 13, 2024
lagano roxanne
sold
-532,177
186
-2,848
executive vice president
Feb 12, 2024
lagano roxanne
sold
-71,779
197
-363
executive vice president
Feb 10, 2024
reed willie m
acquired
-
-
1,463
-

1–10 of 50

Which funds bought or sold ZTS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 07, 2024
Lipe & Dalton
added
23.4
52,000
938,000
 0.48%
May 07, 2024
BANK PICTET & CIE (ASIA) LTD
reduced
-80.93
-23,032,100
4,500,990
 0.35%
May 07, 2024
NorthRock Partners, LLC
added
36.41
138,997
959,002
 0.08%
May 07, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
47.96
7,006,630
33,101,700
 0.01%
May 07, 2024
Tranquility Partners, LLC
reduced
-1.51
-267,084
1,449,650
 0.56%
May 07, 2024
O'Dell Group, LLC
sold off
-100
-50,132
-
 -%
May 07, 2024
Empowered Funds, LLC
added
152
1,460,600
2,713,110
 0.02%
May 07, 2024
Smithfield Trust Co
reduced
-3.13
-59,000
306,000
 0.02%
May 07, 2024
WILBANKS SMITH & THOMAS ASSET MANAGEMENT LLC
added
2.7
-1,605,400
11,823,800
 0.33%
May 07, 2024
SilverOak Wealth Management LLC
unchanged
-
-99,432
597,481
 0.15%

1–10 of 47

Are Funds Buying or Selling ZTS?

Are funds buying ZTS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ZTS
No. of Funds

ZTS Alerts

Unveiling Zoetis Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
8.78%
40,332,692
SC 13G/A
Jan 26, 2024
blackrock inc.
7.9%
36,492,748
SC 13G/A
Feb 09, 2023
vanguard group inc
7.91%
36,850,763
SC 13G/A
Feb 06, 2023
blackrock inc.
8.6%
40,082,444
SC 13G/A
Feb 03, 2022
blackrock inc.
8.5%
40,315,810
SC 13G/A
Feb 10, 2021
vanguard group inc
7.79%
37,023,889
SC 13G/A
Feb 01, 2021
blackrock inc.
8.6%
40,720,915
SC 13G/A
Feb 12, 2020
vanguard group inc
7.85%
37,400,083
SC 13G/A
Feb 06, 2020
blackrock inc.
8.7%
41,563,670
SC 13G/A

Recent SEC filings of Zoetis Inc

View All Filings
Date Filed Form Type Document
May 08, 2024
DEFA14A
DEFA14A
May 07, 2024
144
Notice of Insider Sale Intent
May 06, 2024
DEFA14A
DEFA14A
May 02, 2024
8-K
Current Report
May 02, 2024
10-Q
Quarterly Report
Apr 18, 2024
4
Insider Trading
Apr 18, 2024
144
Notice of Insider Sale Intent
Apr 16, 2024
8-K
Current Report
Apr 10, 2024
DEF 14A
DEF 14A
Apr 10, 2024
ARS
ARS

Peers (Alternatives to Zoetis Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
JNJ
358.5B
85.6B
 -1.74% -7.51%
9.32
4.19
 5.68% 202.39%
MRK
328.0B
61.4B
 2.34% 10.30%
142.26
5.34
 6.11% -82.30%
AMGN
164.9B
29.5B
 14.19% 31.13%
43.82
5.58
 12.76% -52.47%
PFE
160.3B
57.8B
 6.40% -25.71%
127.84
2.77
 76.51% -86.81%
GILD
80.9B
27.4B
 -6.51% -17.64%
166.89
2.95
 1.51% -91.32%
TEVA
17.8B
16.0B
 10.77% 72.86%
-36.03
1.11
 7.23% 71.10%
MID-CAP
PRGO
4.2B
4.6B
 -2.02% -10.81%
-550.77
0.93
 -0.06% 94.55%
ALKS
4.1B
1.7B
 -7.02% -22.02%
9.39
2.36
 54.01% 364.56%
BHC
2.6B
9.0B
 -27.55% 19.80%
-5.66
0.29
 10.01% -27.45%
AMPH
2.0B
644.4M
 2.87% 15.89%
14.77
3.15
 29.14% 50.51%
SMALL-CAP
TLRY
1.5B
743.2M
 -25.10% -28.68%
-4.27
2.02
 24.65% 80.36%
TXMD
23.3M
1.3M
 -6.48% -47.40%
-2.27
17.89
 -98.14% -109.18%
ACRX
17.5M
-
 -11.21% 50.12%
-0.95
0.22
 2882.68% -138.52%
AGRX
2.7M
19.6M
 5.13% -93.31%
-0.19
0.14
 80.00% 43.08%
ACOR
1.1M
117.6M
 -57.29% -90.96%
0
0.01
 -0.79% -283.60%

Zoetis Inc News

Latest updates
MarketBeat • 4 hours ago
Sawgrass Asset Management LLC Has $11.02 Million Holdings in Zoetis Inc. (NYSE:ZTS)
GlobeNewswire • 15 hours ago
Zoetis (ZTS) Stock Declines Amid Concerns Over Arthritis Drugs Impacting Pets - Hagens Berman
MarketBeat • 23 hours ago
Cullen Frost Bankers Inc. Has $31.21 Million Stock Position in Zoetis Inc. (NYSE:ZTS)
Yahoo New Zealand News • 27 hours ago
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
Defense World • 46 hours ago
Zoetis (NYSE:ZTS) Trading Down 0.5% After Analyst Downgrade
Yahoo Finance • 06 May 2024 • 01:00 pm
Is Trending Stock Zoetis Inc. (ZTS) a Buy Now?
Simply Wall St • 04 May 2024 • 01:24 pm
The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Yahoo New Zealand News • 03 May 2024 • 06:57 pm
Is a Surprise Coming for Zoetis (ZTS) This Earnings Season?
Seeking Alpha • 03 May 2024 • 06:37 pm
Zoetis Long Term Buy Despite Safety Concerns (NYSE:ZTS)
Seeking Alpha • 02 May 2024 • 03:40 pm
Zoetis stock gains on Q1 beat (NYSE:ZTS)

Zoetis Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-1.0%2,1902,2132,1512,1802,0002,0402,0022,0521,9861,9671,9901,9481,8711,8071,7861,5481,5341,6741,5841,5471,455
  S&GA Expenses-3.2%547565525556505514501529465593504495409520424393389472391406369
EBITDA Margin-0.5%0.43*0.43*0.43*0.43*0.41*0.41*0.41*0.40*0.41*0.41*0.40*0.41*---------
Interest Expenses15.3%68.0059.0059.0058.0063.0062.0053.0053.0053.0054.0056.0057.0057.0058.0062.0058.0053.0056.0056.0055.0056.00
Income Taxes16.5%14812712120214613213914113393.0010712512962.0011810674.0053.0095.0084.0069.00
Earnings Before Taxes14.9%747650717872697592667670727506659636687420597482497437528455381
EBT Margin-0.5%0.34*0.34*0.34*0.34*0.32*0.33*0.32*0.32*0.32*0.32*0.32*0.32*---------
Net Income14.1%599525596671552461529529595414552512559359479377423384433371312
Net Income Margin-0.2%0.27*0.27*0.27*0.27*0.26*0.26*0.26*0.26*0.26*0.26*0.26*0.26*---------
Free Cashflow-34.9%45569957917.00326570372190194511534368---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets0.4%14,34814,28614,10613,74913,75414,90013,67413,77013,86013,90013,70514,06913,79613,60013,72513,06911,52811,54511,27210,98610,883
  Current Assets0.3%6,3596,3436,2226,1836,2697,5066,5516,6516,8376,9306,6827,0486,7946,6116,7576,2854,7724,7484,6184,4844,379
    Cash Equivalents-3.2%1,9752,0411,7541,7172,1093,5812,5072,6523,1353,4853,2743,6583,6023,6043,6543,3531,9511,9341,8151,7551,728
  Inventory3.4%2,6512,5642,7442,7012,5632,3452,3032,2052,0571,9231,8751,8021,7001,6281,6261,5841,4811,4101,4391,4041,361
  Net PPE1.5%3,2513,2043,0923,0112,9132,7532,6232,5592,4872,4222,3382,2862,2272,2022,0992,0111,9771,9401,8131,7391,683
  Goodwill0%2,7592,7592,7622,7142,7382,7462,6922,7202,6852,6822,7032,7182,7072,6942,6902,6292,5832,5922,5502,5052,522
Liabilities0.0%9,2969,2959,0329,1289,26310,5229,0129,1909,2029,3569,0249,7179,7049,83610,11810,0828,7758,8378,5948,5758,566
  Current Liabilities1.1%1,9091,8891,6081,7691,9153,1672,8803,0513,0341,7971,4712,0912,0662,1702,4001,8111,7211,8061,0521,0751,082
  Short Term Borrowings700.0%24.003.002.002.003.002.003.002.00---4.004.004.001.001.00-----
  Long Term Debt0.0%6,5626,5646,5526,5556,5596,5525,2105,2215,2286,5926,5926,5926,5876,5956,5957,1945,9635,9476,4476,4466,444
    LT Debt, Current------1,3501,3501,3501,350--6006006001,100500-500---
    LT Debt, Non Current-100.0%-6,5646,5526,5556,5596,5525,2105,2215,2286,5926,5926,5926,5876,5956,5957,1945,9635,9476,4476,4466,444
Shareholder's Equity1.1%5,0524,9975,0784,6214,4914,4054,6624,5804,6584,5444,6814,3524,0923,7733,6072,9872,7532,7082,6782,4112,317
  Retained Earnings3.9%10,69610,29510,1409,5439,0458,6688,5338,0047,6287,1867,0446,4926,0995,6595,5265,0484,7644,4274,2173,7883,495
  Additional Paid-In Capital-0.6%1,1261,1331,1161,0981,0791,0881,0731,0591,0461,0681,0561,0441,0301,0651,0401,0301,0171,0441,0311,0191,008
Accumulated Depreciation3.0%2,6732,5942,5292,4472,3742,2972,2322,1932,1412,0722,1132,0642,0121,9521,8941,8181,7691,7371,7251,6851,642
Shares Outstanding-0.3%457458460461462464468470472474475475---------
Minority Interest0%-6.00-6.00-4.00-4.00-3.00-2.00-1.00--1.002.002.003.004.005.005.00-----
Float----79,346---80,550---88,374---65,094---54,228-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-33.7%595897724183549741526336309679653481400718562438408582506318389
  Share Based Compensation5.9%18.0017.0017.0017.009.0016.0015.0015.0016.0014.0015.0016.0013.0013.0014.0016.0016.0016.0016.0017.0018.00
Cashflow From Investing37.6%-131-210-271-80.00-216-438-124-203-118-142-114-139-63.00-177-174-164-57.00-213-209-59.00-23.00
Cashflow From Financing-32.0%-524-397-416-494-1,802780-529-610-545-314-919-290-339-597-93.001,141-328-250-232-226-243
  Buy Backs44.3%339235250324283405377451361198198166181---250176150150150
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ZTS Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue$ 2,190$ 2,000
Costs and expenses:  
Cost of sales643588
Selling, general and administrative expenses547505
Research and development expenses162142
Amortization of intangible assets3737
Restructuring charges and certain acquisition-related costs421
Interest expense, net of capitalized interest5863
Other (income)/deductions—net(8)(53)
Income before provision for taxes on income[1]747697
Provision for taxes on income148146
Net income before allocation to noncontrolling interests599551
Less: Net loss attributable to noncontrolling interests0(1)
Net income attributable to Zoetis Inc.$ 599$ 552
Earnings per share attributable to Zoetis Inc. stockholders:  
Basic (in dollars per share)$ 1.31$ 1.19
Diluted (in dollars per share)$ 1.31$ 1.19
Weighted-average common shares outstanding:  
Basic (in shares)458.0463.5
Diluted (in shares)458.8464.6
Dividends paid per common share (in dollars per share)$ 0.432$ 0.375
[1]Defined as income before provision for taxes on income.

ZTS Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Assets  
Cash and cash equivalents[1]$ 1,975$ 2,041
Accounts receivable, less allowance for doubtful accounts of $20 in 2024 and $18 in 20231,2931,304
Inventories2,6512,564
Other current assets440434
Total current assets6,3596,343
Property, plant and equipment, less accumulated depreciation of $2,673 in 2024 and $2,594 in 20233,2513,204
Operating lease right of use assets225230
Goodwill2,7592,759
Identifiable intangible assets, less accumulated amortization1,2951,338
Noncurrent deferred tax assets232206
Other noncurrent assets227206
Total assets14,34814,286
Liabilities and Equity  
Short-term borrowings243
Accounts payable405411
Dividends payable198198
Accrued expenses691683
Accrued compensation and related items272382
Income taxes payable230110
Other current liabilities89102
Total current liabilities1,9091,889
Long-term debt, net of discount and issuance costs6,5626,564
Noncurrent deferred tax liabilities136146
Operating lease liabilities184188
Other taxes payable277271
Other noncurrent liabilities228237
Total liabilities9,2969,295
Commitments and contingencies (Note 15)
Stockholders’ equity:  
Common stock, $0.01 par value: 6,000,000,000 authorized; 501,891,243 and 501,891,243 shares issued; 456,947,205 and 458,367,358 shares outstanding at March 31, 2024, and December 31, 2023, respectively55
Treasury stock, at cost, 44,944,038 and 43,523,885 shares of common stock at March 31, 2024 and December 31, 2023, respectively(5,928)(5,597)
Additional paid-in capital1,1261,133
Retained earnings10,69610,295
Accumulated other comprehensive loss(841)(839)
Total Zoetis Inc. equity5,0584,997
Equity attributable to noncontrolling interests(6)(6)
Total equity5,0524,991
Total liabilities and equity$ 14,348$ 14,286
[1]As of March 31, 2024 and December 31, 2023, includes $2 million of restricted cash.

About Zoetis Inc

ZTS
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
 CEO
 WEBSITEzoetis.com
 INDUSTRYPharmaceuticals
 EMPLOYEES13800

Zoetis Inc Frequently Asked Questions

What is the ticker symbol for Zoetis Inc? What does ZTS stand for in stocks?

ZTS is the stock ticker symbol of Zoetis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Zoetis Inc (ZTS)?

As of Wed May 08 2024, market cap of Zoetis Inc is 75.28 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ZTS stock?

You can check ZTS's fair value in chart for subscribers.

What is the fair value of ZTS stock?

You can check ZTS's fair value in chart for subscribers. The fair value of Zoetis Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Zoetis Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ZTS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Zoetis Inc a good stock to buy?

The fair value guage provides a quick view whether ZTS is over valued or under valued. Whether Zoetis Inc is cheap or expensive depends on the assumptions which impact Zoetis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ZTS.

What is Zoetis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, ZTS's PE ratio (Price to Earnings) is 31.48 and Price to Sales (PS) ratio is 8.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ZTS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Zoetis Inc's stock?

In the past 10 years, Zoetis Inc has provided 0.191 (multiply by 100 for percentage) rate of return.